高盛-爱尔眼科Aier Eye Hospital (300015.SZ) China+ Conference 2024 – Key Takeaways Weak demand continued, low visibility on inflection09122024.docx

下载文档

0
0
约3.75万字
约 12页
2024-11-30 发布于北京
举报
版权申诉
保障服务

高盛-爱尔眼科Aier Eye Hospital (300015.SZ) China+ Conference 2024 – Key Takeaways Weak demand continued, low visibility on inflection09122024.docx

1、本文档共12页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

12September2024|7:21AMCST

AierEyeHospital(300015.SZ):China+Conference2024–KeyTakeaways:Weakdemandcontinued,lowvisibilityonin?ection

Research|Equity

TianyiYan

+86(21)2401-8609|

tianyi.yan@

GoldmanSachs(China)SecuritiesCompanyLimited

Presenters:Mr.Jiang,IR

ZiyiChen

+852-2978-0526|ziyi.chen@GoldmanSachs(Asia)L.L.C.

BottomLine:WehostedAierEyeHospitalatourGSChina+Conference2024,

MichaelZheng

wherethecompanysharedmoreinsightson:1)Jul-Augtrendupdatesonrefractive

+86(21)2401-8928|

michael.zheng@

surgery/optometryservice,2)volumegrowthandpricechangepostIOLnational

GoldmanSachs(China)SecuritiesCompanyLimited

VBP.Ingeneral,weseeweakdemandcontinuedinbusyseason,withlowvisibility

JennyDu

onin?ection.Meanwhile,cataractsurgeryremainedstabledespitehighbaselast

+86(21)2401-8978|

jenny.x.du@

GoldmanSachs(China)Securities

yearandgradualimplementationofIOLnationalVBP.

CompanyLimited

KeyTakeaways

nWeakconsumptioncontinued:Perthecompany,itsrevenuegrowthintop-tiercitieswaslowerthanlower-tiercitiesmainlyduetohigherrevenuesharefrom

refractivesurgeriesinlargecities,whichwasmostlyimpactedamidstmacro

environmentuncertainties.Accordingtothecompany,refractivesurgery

segmentremainedweakinbusyseason(Jul-Aug)inlinewith1H24

performance,owingtolowerrevenuesharefromSMILE.However,itobservedstabilizingpricingcompetitionaswellassomesmallerplayersexitingthe

market.Percompany,ICLsurgerycontributed20%-25%oftotalrefractive

_surgeryrevenuewhileSMILEcontributed40%-45%asof1H24.Additionally,OKlensesprescriptionremained?attish(vs.20%y/ygrowthfromdefocuslensesascheapersubstitutionforteenagermyopiacontrol).

nStableperformancefromcataractdespitehighbaseandVBP:Aierdeliveredhigher-than-averagegrowthfromcataractsurgeriesin1H24(vs.?attishindustryvolumein1H24).Per